|
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Clinical research trials and Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer. Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer clinical trial. Human subjects often get the best healthcare possible for their Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer  Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
For Condition: Leukemia,Lymphoma,Head and Neck Cancer,Lung Cancer,Eye Cancer,Gastrointestinal Cancer,Oral Cancer,Reproductive Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Eastern Cooperative Oncology Group
Synopsis: RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking. PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated stop-smoking program with the usual care for patients receiving treatment for early-stage cancer.
Details: OBJECTIVES: I. Compare the efficacy of brief physician-initiated smoking cessation strategies vs usual care in patients with early stage cancer who are undergoing treatment in clinical oncology settings. II. Compare the sociodemographic, smoking history, and health status correlates of smoking cessation in patients treated with these regimens. III. Determine the feasibility of conducting a cancer prevention and control study in a cooperative group setting by monitoring adherence to the smoking-cessation strategies. PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive usual care (no special intervention). Arm II: Patients receive smoking-cessation therapy based on the 4-step intervention plan in the "Manual for Physicians" published by the National Cancer Institute. The smoking cessation coordinator and physician provide self-quitting advice and support to the patient via counseling, self-help materials, and referral to a smoking cessation counselor at the Cancer Information Service (CIS). Patients receive nicotine replacement, if indicated. Patients who express an interest in more intensive treatment are referred to local American Cancer Society or American Lung Association clinics and/or advised to call the CIS for additional local program referrals. All patients are followed at 6 and 12 months. Patients who report that they are still smoking and interested in help to quit smoking at the 12-month follow-up interview are encouraged to return to their physicians and contact the CIS for additional help quitting or for a referral to more intensive or specialized treatments in their area. PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 19 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of stage I or II bladder, colorectal, head and neck, lung, or other cancer OR Diagnosis of stage I-III testicular cancer OR Diagnosis of stage I-IV breast cancer, prostate cancer, or lymphoma Must have smoked 1 or more cigarettes within the past month or define self as a smoker Hormone receptor status: Not specified --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior participation in the pilot phase study --Patient Characteristics-- Age: 19 and over Sex: Not specified Menopausal status: Not specified Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No history of recent heart attack Other: - Not pregnant - No other imminent medical needs requiring referral to a more intensive smoking cessation regimen
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PaulEngstrom, Study Chair, Eastern Cooperative Oncology Group
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Additional Information:
Study ID Numbers: CDR0000078281; E-1Y92,NCI-P93-0042
Study Start Date: June 1992
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002520
Other Eye Cancer Studies:
1. Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
2. Fludarabine, Total-body Irradiation, Donor Peripheral Stem Cell Transplantation, and Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
3. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
4. Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
5. Bryostatin 1 Plus Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
Related Studies:
Other Eye Cancer Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
|
|
|
|
|
|
|
|
